BioXcel Therapeutics' BXCL701 Receives FDA Fast Track Designation: A New Hope in the Battle Against Small Cell Neuroendocrine Prostate Cancer.
Share this post
Therapeutics Company Receives FDA Fast Track…
Share this post
BioXcel Therapeutics' BXCL701 Receives FDA Fast Track Designation: A New Hope in the Battle Against Small Cell Neuroendocrine Prostate Cancer.